文献速递消化系统肿瘤

阿司匹林与其他血小板聚集抑制剂使用与结直肠癌患者生存关联的差异

The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
PubMed 文献 · Eur J Cancer · 2017-03-26

该观察性研究将荷兰综合癌症组织数据与PHARMO数据库网络链接,纳入9196例结直肠癌患者,分析阿司匹林及非阿司匹林血小板聚集抑制剂(TAI)使用与总生存的关联。结果显示,诊断后使用阿司匹林与总生存显著改善相关(HR 0.41,95%CI 0.37-0.47),而非阿司匹林TAI使用与生存无显著关联(HR 0.92,95%CI 0.70-1.22);双联使用者较单用阿司匹林无额外生存获益。

要点

  • 诊断后使用阿司匹林与结直肠癌患者总生存显著改善相关,HR 0.41(95%CI 0.37-0.47)。
  • 使用非阿司匹林TAI与总生存无显著关联,HR 0.92(95%CI 0.70-1.22)。
  • 阿司匹林联合其他TAI的双联使用者较单用阿司匹林无额外生存获益。

核心结论

  • 结直肠癌诊断后使用阿司匹林与显著降低的死亡风险相关,校正潜在混杂因素后该效应仍显著。
  • 使用阿司匹林联合另一种TAI的患者未观察到额外生存获益。

研究设计与样本

  • 观察性研究,将荷兰综合癌症组织数据与PHARMO数据库网络链接。
  • 共识别9196例结直肠癌患者,其中1766例在诊断后使用TAI。
  • 使用Cox回归模型,以(非)阿司匹林TAI使用作为时变协变量分析总生存关联。

主要发现

  • 阿司匹林使用与总生存显著改善相关,HR 0.41(95%CI 0.37-0.47)。
  • 非阿司匹林TAI使用与生存无显著关联,HR 0.92(95%CI 0.70-1.22)。
  • 双联使用者较单用阿司匹林患者无总生存改善。
  • 非阿司匹林TAI主要为氯吡格雷和双嘧达莫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have suggested that the association between aspirin and improved cancer survival is mediated through the mechanism of aspirin as thrombocyte aggregation inhibitors (TAI). The aim of this study was to provide epidemiological evidence for this mechanism assessing the association between overall survival and the use of aspirin and non-aspirin TAI in patients with colorectal cancer. METHODS: In this observational study, data from the Netherlands Comprehensive Cancer Organisation were linked to PHARMO Database Network. Patients using aspirin or aspirin in combination with non-aspirin TAI (dual users) were selected and compared with non-users. The association between overall survival and the use of (non-)aspirin TAI was analysed using Cox regression models with the use of (non-)aspirin TAI as a time-varying covariate. RESULTS: In total, 9196 patients were identified with colorectal cancer and 1766 patients used TAI after diagnosis. Non-aspirin TAI were mostly clopidogrel and dipyridamole. Aspirin use was associated with a significant increased overall survival and hazard ratio (HR) 0.41 (95% confidence interval [CI] 0.37-0.47), and the use of non-aspirin TAI was not associated with survival of HR 0.92 (95% CI 0.70-1.22). Dual users did not have an improved overall survival when compared with patients using solely aspirin. CONCLUSIONS: Aspirin use after diagnosis of colorectal cancer was associated with significantly lower mortality rates and this effect remained significant after adjusting for potential confounders. No additional survival benefit was observed in patients using both aspirin and another TAI.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Frouws MA, Rademaker E, Bastiaannet E, et al. The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. Eur J Cancer. 2017. PMID: 28350995. doi:10.1016/j.ejca.2017.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。